Newsletter
Shares of Sun Pharma fell nearly 4% on Friday, after reports say it is moving ahead with a $12 billion bid for Organon.
Organon is a global healthcare company focused on women’s health, offering treatments in areas like reproductive and maternal care across 140+ markets.
What’s brewing: the company has been on Sun Pharma’s radar for some time, with interest picking up after it sold a key product as part of a strategy shift.
The potential deal, if completed, would be Sun Pharma’s largest acquisition.
Why did the shares fall: investors are cautious because this is a very large deal ($12 billion), and Sun Pharma may need to take on significant debt, which could pressure its balance sheet.
There are also concerns about integrating a global company like Organon, which operates across 140+ markets, adding execution risk in the near term.
Adding to worries, Organon itself is not performing strongly, its stock is down 19% this year and trades at a relatively low valuation, signalling limited growth expectations.
Big picture: despite near-term concerns, pharma M&A is clearly heating up, deal values jumped 79% in 2025, with average deal sizes up over 80%, as companies place bigger, strategic bets.
Alpha Sense
